Sisram Medical
Market Cap
HK$1.7b
Last Updated
2020/02/16 13:08 UTC
Data Sources
Company Financials
Executive Summary
Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa.
Rewards
Risk Analysis
Snowflake Analysis
Undervalued with solid track record.
Similar Companies
Share Price & News
How has Sisram Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1696 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.5%
1696
1.1%
HK Medical Equipment
1.7%
HK Market
1 Year Return
-7.3%
1696
45.7%
HK Medical Equipment
-2.9%
HK Market
Return vs Industry: 1696 underperformed the Hong Kong Medical Equipment industry which returned 45.7% over the past year.
Return vs Market: 1696 underperformed the Hong Kong Market which returned -2.9% over the past year.
Shareholder returns
| 1696 | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.5% | 1.1% | 1.7% |
| 30 Day | -3.7% | 1.0% | -4.2% |
| 90 Day | -8.0% | 14.9% | 4.6% |
| 1 Year | -5.0%-7.3% | 47.2%45.7% | 0.7%-2.9% |
| 3 Year | n/a | 49.9%45.0% | 15.3%3.6% |
| 5 Year | n/a | 52.0%43.8% | 15.9%-3.5% |
Price Volatility Vs. Market
How volatile is Sisram Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
How Many Sisram Medical Ltd (HKG:1696) Shares Did Insiders Buy, In The Last Year?1 month ago | Simply Wall St
I Ran A Stock Scan For Earnings Growth And Sisram Medical (HKG:1696) Passed With Ease1 month ago | Simply Wall St
Sisram Medical's (HKG:1696) Earnings Are Growing But Is There More To The Story?Valuation
Is Sisram Medical undervalued compared to its fair value and its price relative to the market?
42.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1696 (HK$3.92) is trading below our estimate of fair value (HK$6.81)
Significantly Below Fair Value: 1696 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1696 is good value based on its PE Ratio (9.4x) compared to the Medical Equipment industry average (18.5x).
PE vs Market: 1696 is good value based on its PE Ratio (9.4x) compared to the Hong Kong market (10.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1696's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1696 is good value based on its PB Ratio (0.7x) compared to the HK Medical Equipment industry average (2.6x).
Next Steps
Future Growth
How is Sisram Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
27.2%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sisram Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine whether Sisram Medical is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Sisram Medical competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Sisram Medical performed over the past 5 years?
30.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1696 has high quality earnings.
Growing Profit Margin: 1696's current net profit margins (14.8%) are higher than last year (9.7%).
Past Earnings Growth Analysis
Earnings Trend: 1696's earnings have grown significantly by 30.2% per year over the past 5 years.
Accelerating Growth: 1696's earnings growth over the past year (64.2%) exceeds its 5-year average (30.2% per year).
Earnings vs Industry: 1696 earnings growth over the past year (64.2%) exceeded the Medical Equipment industry 43.4%.
Return on Equity
High ROE: 1696's Return on Equity (7.6%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Sisram Medical's financial position?
Financial Position Analysis
Short Term Liabilities: 1696's short term assets ($196.9M) exceed its short term liabilities ($41.4M).
Long Term Liabilities: 1696's short term assets ($196.9M) exceed its long term liabilities ($25.5M).
Debt to Equity History and Analysis
Debt Level: 1696's debt to equity ratio (0.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 1696's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 1696's debt is well covered by operating cash flow (735.9%).
Interest Coverage: 1696 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: 1696 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 1696's debt is covered by short term assets (assets are 66.6x debt).
Next Steps
Dividend
What is Sisram Medical's current dividend yield, its reliability and sustainability?
2.57%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: 1696's dividend (2.58%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.27%).
High Dividend: 1696's dividend (2.58%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.34%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether 1696's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if 1696's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (24.2%), 1696's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Lior Dayan (49yo)
2.7yrs
Tenure
US$884,000
Compensation
Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and is responsible for its overall and day-to-day management and development. Mr. Dayan ...
CEO Compensation Analysis
Compensation vs Market: Lior's total compensation ($USD884.00K) is above average for companies of similar size in the Hong Kong market ($USD284.67K).
Compensation vs Earnings: Lior's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 3.8yrs | no data | no data | |
| CEO & Executive Director | 2.7yrs | US$884.00k | 0.026% $444.9k | |
| CFO & Executive Director | 1.1yrs | no data | no data | |
| Chief Operating Officer | 1.8yrs | no data | no data | |
| Chief Strategy Officer | 1.9yrs | no data | no data | |
| Company Secretary | 0.2yrs | no data | no data |
1.8yrs
Average Tenure
50yo
Average Age
Experienced Management: 1696's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 3.8yrs | no data | no data | |
| CEO & Executive Director | 2.7yrs | US$884.00k | 0.026% $444.9k | |
| CFO & Executive Director | 1.1yrs | no data | no data | |
| Independent Non-Executive Director | 2.5yrs | US$25.00k | no data | |
| Non-Executive Director | 3.3yrs | no data | no data | |
| Non-Executive Director | 3.8yrs | no data | no data | |
| Independent Non-Executive Director | 2.5yrs | US$25.00k | no data | |
| Independent Non-Executive Director | 2.5yrs | US$25.00k | no data | |
| Independent Non-Executive Director | 2.5yrs | US$25.00k | no data | |
| Non-Executive Director | 0.5yrs | no data | no data |
2.5yrs
Average Tenure
44.5yo
Average Age
Experienced Board: 1696's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.1%.
Top Shareholders
Company Information
Sisram Medical Ltd's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sisram Medical Ltd
- Ticker: 1696
- Exchange: SEHK
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: HK$1.733b
- Shares outstanding: 442.16m
- Website: https://www.sisram-medical.com
Number of Employees
Location
- Sisram Medical Ltd
- 14 Halamish Street
- Caesarea Industrial Park
- Caesarea
- 38900
- Israel
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1696 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Sep 2017 |
Biography
Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers a portfolio of treatment systems for non-invasive medical aesthetic treatments, including hair removal, skin rejuvenation, skin resurfacing, vascular and pigmented lesions treatment, tattoo removal, acne treatment, cellulite reduction, body contouring, and skin tightening; and minimally invasive treatments, such as laser-based liposuction, as well as treatment of varicose veins, ear, nose, and throat procedures. The company also provides beauty product line treatment systems, such as Rejuve and Reshape; and distributes medical equipment. It offers its products under the Alma, Soprano, Harmony, Accent, and FemiLift brands. The company sells its products directly to treatment providers, such as plastic surgeons and dermatologists, primary care physicians, obstetricians, gynecologists, and aestheticians, as well as ear, nose, and throat specialists; and through distributors. The company was founded in 2013 and is headquartered in Caesarea, Israel. Sisram Medical Ltd operates as a former subsidiary of Ample Up Limited.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 13:08 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.